Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May;10(5):293-302.
doi: 10.1038/nrendo.2014.29. Epub 2014 Mar 25.

Insulin resistance and hyperglycaemia in cardiovascular disease development

Affiliations
Review

Insulin resistance and hyperglycaemia in cardiovascular disease development

Markku Laakso et al. Nat Rev Endocrinol. 2014 May.

Abstract

The prevalence of diabetes mellitus will likely increase globally from 371 million individuals in 2013 to 552 million individuals in 2030. This epidemic is mainly attributable to type 2 diabetes mellitus (T2DM), which represents about 90-95% of all cases. Cardiovascular disease is the leading cause of mortality among individuals with diabetes mellitus, and >50% of patients will die from a cardiovascular event-especially coronary artery disease, but also stroke and peripheral vascular disease. Classic risk factors such as elevated levels of LDL cholesterol and blood pressure, as well as smoking, are risk factors for adverse cardiovascular events in patients with type 1 diabetes mellitus (T1DM) and T2DM to a similar degree as they are in healthy individuals. Patients with T1DM develop insulin resistance in the months after diabetes mellitus diagnosis, and patients with T2DM typically develop insulin resistance before hyperglycaemia occurs. Insulin resistance and hyperglycaemia, in turn, further increase the risk of adverse cardiovascular events. This Review discusses the mechanisms by which T1DM and T2DM can lead to cardiovascular disease and how these relate to the risk factors for coronary artery disease.

PubMed Disclaimer

References

    1. N Engl J Med. 2005 Dec 22;353(25):2643-53 - PubMed
    1. Lancet. 2008 May 24;371(9626):1800-9 - PubMed
    1. Ann N Y Acad Sci. 2013 Apr;1281:51-63 - PubMed
    1. Cell Metab. 2011 Nov 2;14(5):575-85 - PubMed
    1. Diabetologia. 2013 Jul;56(7):1462-70 - PubMed

MeSH terms